-DOCSTART- -X- O
Drug -X- _ O
repurposing -X- _ O
offers -X- _ O
an -X- _ O
expedited -X- _ O
and -X- _ O
economical -X- _ O
route -X- _ O
to -X- _ O
develop -X- _ O
new -X- _ O
clinical -X- _ O
therapeutics -X- _ O
in -X- _ O
comparison -X- _ O
to -X- _ O
traditional -X- _ O
drug -X- _ O
development. -X- _ O
Growth-based -X- _ O
high-throughput -X- _ O
screening -X- _ O
is -X- _ O
concomitant -X- _ O
with -X- _ O
drug -X- _ O
repurposing -X- _ O
and -X- _ O
enables -X- _ O
rapid -X- _ O
identification -X- _ O
of -X- _ O
new -X- _ O
therapeutic -X- _ O
uses -X- _ O
for -X- _ O
investigated -X- _ O
drugs -X- _ O
; -X- _ O
however -X- _ O
, -X- _ O
this -X- _ O
traditional -X- _ O
method -X- _ O
is -X- _ O
not -X- _ O
compatible -X- _ O
with -X- _ O
microorganisms -X- _ O
with -X- _ O
abnormal -X- _ O
growth -X- _ O
patterns -X- _ O
such -X- _ O
as -X- _ O
Staphylococcus -X- _ B-Patient
aureus -X- _ I-Patient
small-colony -X- _ I-Patient
variants -X- _ I-Patient
( -X- _ I-Patient
SCV -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
SCV -X- _ O
subpopulations -X- _ O
are -X- _ O
auxotrophic -X- _ O
for -X- _ O
key -X- _ O
compounds -X- _ O
in -X- _ O
biosynthetic -X- _ O
pathways -X- _ O
, -X- _ O
which -X- _ O
result -X- _ O
in -X- _ O
low -X- _ O
growth -X- _ O
rate. -X- _ O
SCV -X- _ O
formation -X- _ O
is -X- _ O
also -X- _ O
associated -X- _ O
with -X- _ O
reduced -X- _ O
antibiotic -X- _ O
susceptibility -X- _ O
, -X- _ O
and -X- _ O
the -X- _ O
SCVâ€™s -X- _ O
ability -X- _ O
to -X- _ O
revert -X- _ O
to -X- _ O
the -X- _ O
normal -X- _ O
cell -X- _ O
growth -X- _ O
state -X- _ O
is -X- _ O
thought -X- _ O
to -X- _ O
contribute -X- _ O
to -X- _ O
recurrence -X- _ O
of -X- _ O
S. -X- _ O
aureus -X- _ O
infections. -X- _ O
Thus -X- _ O
, -X- _ O
there -X- _ O
is -X- _ O
a -X- _ O
critical -X- _ O
need -X- _ O
to -X- _ O
identify -X- _ O
antimicrobial -X- _ O
agents -X- _ O
that -X- _ O
are -X- _ O
potent -X- _ O
against -X- _ O
SCV -X- _ O
in -X- _ O
order -X- _ O
to -X- _ O
effectively -X- _ O
treat -X- _ O
chronic -X- _ O
infections. -X- _ O
Accordingly -X- _ O
, -X- _ O
here -X- _ O
we -X- _ O
describe -X- _ O
adapting -X- _ O
an -X- _ O
adenylate -X- _ O
kinase -X- _ O
( -X- _ O
AK -X- _ O
) -X- _ O
-based -X- _ O
cell -X- _ O
death -X- _ O
reporter -X- _ O
assay -X- _ O
to -X- _ O
identify -X- _ O
members -X- _ O
of -X- _ O
a -X- _ O
Food -X- _ B-Intervention
and -X- _ I-Intervention
Drug -X- _ I-Intervention
Administration -X- _ I-Intervention
( -X- _ I-Intervention
FDA -X- _ I-Intervention
) -X- _ I-Intervention
-approved -X- _ I-Intervention
drug -X- _ I-Intervention
library -X- _ I-Intervention
that -X- _ O
display -X- _ O
bactericidal -X- _ O
activity -X- _ O
against -X- _ O
S. -X- _ O
aureus -X- _ O
SCV. -X- _ O
Four -X- _ O
library -X- _ O
members -X- _ O
, -X- _ O
daunorubicin -X- _ O
, -X- _ O
ketoconazole -X- _ O
, -X- _ O
rifapentine -X- _ O
, -X- _ O
and -X- _ O
sitafloxacin -X- _ O
, -X- _ O
exhibited -X- _ O
potent -X- _ O
SCV -X- _ B-Outcome
bactericidal -X- _ I-Outcome
activity -X- _ I-Outcome
against -X- _ I-Outcome
a -X- _ I-Outcome
stable -X- _ I-Outcome
S. -X- _ I-Outcome
aureus -X- _ I-Outcome
SCV. -X- _ I-Outcome
Further -X- _ O
investigation -X- _ O
showed -X- _ O
that -X- _ O
sitafloxacin -X- _ O
was -X- _ O
potent -X- _ O
against -X- _ O
methicillin-susceptible -X- _ B-Outcome
and -X- _ I-Outcome
-resistant -X- _ I-Outcome
S. -X- _ I-Outcome
aureus -X- _ I-Outcome
, -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
S. -X- _ B-Outcome
aureus -X- _ I-Outcome
within -X- _ I-Outcome
an -X- _ I-Outcome
established -X- _ I-Outcome
biofilm. -X- _ I-Outcome
Taken -X- _ O
together -X- _ O
, -X- _ O
these -X- _ O
results -X- _ O
demonstrate -X- _ O
the -X- _ O
ability -X- _ O
to -X- _ O
use -X- _ O
the -X- _ O
AK -X- _ O
assay -X- _ O
to -X- _ O
screen -X- _ O
small-molecule -X- _ O
libraries -X- _ O
for -X- _ O
SCV -X- _ O
bactericidal -X- _ O
agents -X- _ O
and -X- _ O
highlight -X- _ O
the -X- _ O
therapeutic -X- _ O
potential -X- _ O
of -X- _ O
sitafloxacin -X- _ O
to -X- _ O
be -X- _ O
repurposed -X- _ O
to -X- _ O
treat -X- _ O
chronic -X- _ O
S. -X- _ O
aureus -X- _ O
infections -X- _ O
associated -X- _ O
with -X- _ O
SCV -X- _ O
and -X- _ O
/ -X- _ O
or -X- _ O
biofilm -X- _ O
growth -X- _ O
states. -X- _ O
IMPORTANCE -X- _ O
Conventional -X- _ O
antibiotics -X- _ O
fail -X- _ O
to -X- _ O
successfully -X- _ O
treat -X- _ O
chronic -X- _ O
osteomyelitis -X- _ O
, -X- _ O
endocarditis -X- _ O
, -X- _ O
and -X- _ O
device-related -X- _ O
and -X- _ O
airway -X- _ O
infections. -X- _ O
These -X- _ O
recurring -X- _ O
infections -X- _ O
are -X- _ O
associated -X- _ O
with -X- _ O
the -X- _ O
emergence -X- _ O
of -X- _ O
SCV -X- _ O
, -X- _ O
which -X- _ O
are -X- _ O
recalcitrant -X- _ O
to -X- _ O
conventional -X- _ O
antibiotics. -X- _ O
Studies -X- _ O
have -X- _ O
investigated -X- _ O
antibiotic -X- _ O
therapies -X- _ O
to -X- _ O
treat -X- _ O
SCV-related -X- _ O
infections -X- _ O
but -X- _ O
have -X- _ O
had -X- _ O
little -X- _ O
success -X- _ O
, -X- _ O
emphasizing -X- _ O
the -X- _ O
need -X- _ O
to -X- _ O
identify -X- _ O
novel -X- _ O
antimicrobial -X- _ O
drugs. -X- _ O
However -X- _ O
, -X- _ O
drug -X- _ O
discovery -X- _ O
is -X- _ O
a -X- _ O
costly -X- _ O
and -X- _ O
time-consuming -X- _ O
process. -X- _ O
An -X- _ O
alternative -X- _ O
strategy -X- _ O
is -X- _ O
drug -X- _ O
repurposing -X- _ O
, -X- _ O
which -X- _ O
could -X- _ O
identify -X- _ O
FDA-approved -X- _ O
and -X- _ O
well-characterized -X- _ O
drugs -X- _ O
that -X- _ O
could -X- _ O
have -X- _ O
off-label -X- _ O
utility -X- _ O
in -X- _ O
treating -X- _ O
SCV. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
we -X- _ O
adapted -X- _ O
a -X- _ O
high-throughput -X- _ O
AK-based -X- _ O
assay -X- _ O
to -X- _ O
identify -X- _ O
4 -X- _ O
FDA-approved -X- _ O
drugs -X- _ O
, -X- _ O
daunorubicin -X- _ O
, -X- _ O
ketoconazole -X- _ O
, -X- _ O
rifapentine -X- _ O
, -X- _ O
and -X- _ O
sitafloxacin -X- _ O
, -X- _ O
which -X- _ O
display -X- _ O
antimicrobial -X- _ O
activity -X- _ O
against -X- _ O
S. -X- _ O
aureus -X- _ O
SCV -X- _ O
, -X- _ O
suggesting -X- _ O
an -X- _ O
avenue -X- _ O
for -X- _ O
drug -X- _ O
repurposing -X- _ O
in -X- _ O
order -X- _ O
to -X- _ O
effectively -X- _ O
treat -X- _ O
SCV-related -X- _ O
infections. -X- _ O
Additionally -X- _ O
, -X- _ O
this -X- _ O
screening -X- _ O
paradigm -X- _ O
can -X- _ O
easily -X- _ O
be -X- _ O
adapted -X- _ O
for -X- _ O
other -X- _ O
drug -X- _ O
/ -X- _ O
chemical -X- _ O
libraries -X- _ O
to -X- _ O
identify -X- _ O
compounds -X- _ O
bactericidal -X- _ O
against -X- _ O
SCV -X- _ O
. -X- _ O

